openPR Logo
Press release

Trastuzumab Biosimilars Market Trends, Top Companies, Share, Growth And Forecast 2033

Trastuzumab Biosimilars Market Trends

Trastuzumab Biosimilars Market Trends

The Business Research Company recently released a comprehensive report on the Global Trastuzumab Biosimilars Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

According to The Business Research Company's, The trastuzumab biosimilars market size has grown exponentially in recent years. It will grow from $4.27 billion in 2023 to $5.43 billion in 2024 at a compound annual growth rate (CAGR) of 27.1%. The growth in the historic period can be attributed to market expansion and global reach, patent expiry and market entry, rapid biosimilar development, clinical efficacy validation, competitive pricing.

The trastuzumab biosimilars market size is expected to see exponential growth in the next few years. It will grow to $14.69 billion in 2028 at a compound annual growth rate (CAGR) of 28.3%. The growth in the forecast period can be attributed to market competition intensification, biosimilar pipeline development, regulatory approvals and standardizations, global market penetration, physician adoption and prescribing patterns. Major trends in the forecast period include improved access, market segmentation strategies, educational campaigns, patient preference for biosimilars, physician acceptance.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Market Drivers and Trends:

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilars market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, about 297,790 new cases of invasive breast cancer will be diagnosed in women in 2023, and about 43,700 women will die from breast cancer in the same year. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that help save money when compared to expensive medicines, thereby driving the trastuzumab biosimilars market.

Major players are continuously focusing on launching new products in untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives, such as new product development, partnerships, and geographical and product portfolio expansion, to maintain their competitive position in the market and better serve the needs of the customers. For instance, in May 2021, Zydus Cadila, an India-based pharmaceutical company, launched the world's first biosimilar form of trastuzumab, emtansine, an antibody drug compound (trastuzumab) that not only slows the growth of cancer cells but also delivers a cytotoxic substance to the cancer cell, aiding in its destruction. It is used to treat breast cancer that is human epidermal growth factor receptor 2 (HER2) positive, which accounts for 20% to 25% of all breast cancers and is quite aggressive.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Major Key Players of the Market:

Pfizer Inc., Outlook Therapeutics lnc., Merck & Co., Amgen Inc., BioXpress Therapeutics SA, Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co.Ltd., Innovent Biologics lnc., STADA Arzneimittel AG, Apotex Inc., Samsungbioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech lnc., Biocon Limited, Sunshine Guojian Pharmaceutical Co. Ltd., Shanghai CP Guojian Pharmaceutical Co.Ltd., Alvotech Holdings S.A, Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., PlantForm Corporation, STC Biologics Ltd., Prestige BioPharma Limited, Protheragen Inc., AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited, Reliance Life Sciences Pvt. Ltd.

Trastuzumab Biosimilars Market 2024 Key Insights:

• The trastuzumab biosimilars market size is expected to see exponential growth in the next few years. It will grow to $14.69 billion in 2028 at a compound annual growth rate (CAGR) of 28.3%.
• Rising Breast And Gastric Cancer Prevalence Drives Trastuzumab Biosimilars Market.
• Companies Focus On Product Launches And Expansion To Fuel Trastuzumab Biosimilars Market Growth
• North America was the largest region in the trastuzumab biosimilars market in 2023

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=3400&type=smp

Contact Us:

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Trastuzumab Biosimilars Market Trends, Top Companies, Share, Growth And Forecast 2033 here

News-ID: 3776701 • Views:

More Releases from The Business research company

Future of the Global Pelvic Inflammatory Disease (PID) Treatment Market: Trends, Innovations, and Key Forecasts Through 2034
Future of the Global Pelvic Inflammatory Disease (PID) Treatment Market: Trends, …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Pelvic Inflammatory Disease (PID) Treatment Market Size Growth Forecast: What to Expect by 2025? Recent advancements indicate a robust expansion within the pelvic inflammatory disease (PID) treatment market, projecting an increase from its 2024 valuation of $4.49 billion to $4.74 billion in 2025, reflecting a steady compound annual growth
Steady Expansion Forecast for Pediatric Brain Tumors Market, Projected to Reach $1.81 Billion by 2029
Steady Expansion Forecast for Pediatric Brain Tumors Market, Projected to Reach …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Pediatric Brain Tumors Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The valuation of the pediatric brain tumors market has seen substantial expansion lately, projected to ascend from $1.3 billion in 2024 to $1.4 billion the following year; this upward trajectory represents a compound annual
Top Market Shifts Transforming the Gonorrhea Therapeutics Market Landscape: Key Insights
Top Market Shifts Transforming the Gonorrhea Therapeutics Market Landscape: Key …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Gonorrhea Therapeutics Market Through 2025? The market encompassing gonorrhea treatments has experienced robust expansion over the past few years, projected to increase from a value of $1.88 billion in 2024 to $1.97 billion in 2025, reflecting a compound annual growth rate of
Rising Prevalence Of Chronic Diseases Drives Growth In The Market Emerges as a Core Driver of the Over The Counter Or OTC Test Market in 2025
Rising Prevalence Of Chronic Diseases Drives Growth In The Market Emerges as a C …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Over The Counter Or OTC Test Market Through 2025? The market encompassing over the counter (OTC) testing solutions has experienced swift expansion lately, projected to elevate from a valuation of $24.1 billion in 2024 to $27.47 billion the following year, reflecting a

All 5 Releases


More Releases for Trastuzumab

Rising Breast And Gastric Cancer Prevalence Drives Trastuzumab Biosimilars Marke …
"The Trastuzumab Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Trastuzumab Biosimilars Market Size and Projected Growth Rate? The trastuzumab biosimilars market has seen rapid growth in recent years. It will grow from $4.27 billion in 2024 to $5.43 billion in 2025,
Leading Growth Driver in the Trastuzumab Biosimilars Market in 2025: Rising Brea …
What Are the Market Size and Growth Forecast for the Trastuzumab Biosimilars Market? The market for trastuzumab biosimilars has witnessed significant expansion in the past few years. The market is projected to increase from $4.27 billion in 2024 to $5.43 billion in 2025, with a compound annual growth rate (CAGR) of 27.1%. The historical growth patterns can be attributed to the expansion and globalization of the market, expiry of patents and
Leading Growth Driver in the Trastuzumab Biosimilars Market in 2025: Rising Brea …
What Are the Market Size and Growth Forecast for the Trastuzumab Biosimilars Market? The market for trastuzumab biosimilars has witnessed significant expansion in the past few years. The market is projected to increase from $4.27 billion in 2024 to $5.43 billion in 2025, with a compound annual growth rate (CAGR) of 27.1%. The historical growth patterns can be attributed to the expansion and globalization of the market, expiry of patents and
Herceptin (Trastuzumab) Market Overview,Recent Devolopment And Forecast During ( …
This report presents an overview of global market for Herceptin (Trastuzumab), capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028. This report researches the key producers of Herceptin (Trastuzumab), also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Herceptin (Trastuzumab), and key regions/countries of
Trastuzumab Biosimilar Market Opportunities and Growth Challenges Report 2022-20 …
Global Trastuzumab Biosimilar Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis Trastuzumab Biosimilar Market Overview The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global Trastuzumab Biosimilar Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as well as the
Trastuzumab Biosimilar Market 2022 | Detailed Report
According to Market Study Report, Trastuzumab Biosimilar Market provides a comprehensive analysis of the Trastuzumab Biosimilar Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5511273 The report provides a comprehensive analysis of company profiles listed below: - Amgen Inc. - Pfizer Inc - Samsung Bioepis -